 RedHill Biopharma Ltd NASDAQ: RDHL announced new data from a prespecified analysis of all oral opaganibs Phase 23 study patients in COVID-19 patients. The data demonstrated that opaganib improved the median time to viral RNA clearance by at least four days. 